





OPEN

Author Correction: The number of osteoclasts in a biopsy specimen can predict the efficacy of neoadjuvant chemotherapy for primary osteosarcoma

Yoshihiro Araki , Norio Yamamoto , Katsuhiko Hayashi , Akihiko Takeuchi , Shinji Miwa , Kentaro Igarashi , Takashi Higuchi , Kensaku Abe , Yuta Taniguchi , Hirotaka Yonezawa , Sei Morinaga , Yohei Asano , Hiroko Ikeda, Takayuki Nojima  & Hiroyuki Tsuchiya 

Correction to: *Scientific Reports* <https://doi.org/10.1038/s41598-020-80504-w>, published online 21 January 2021

The original version of this Article contained errors.

Author names Yoshihiro Araki, Norio Yamamoto, Katsuhiko Hayashi, Akihiko Takeuchi, Shinji Miwa, Kentaro Igarashi, Takashi Higuchi, Kensaku Abe, Yuta Taniguchi, Hirotaka Yonezawa, Sei Morinaga, Yohei Asano, Hiroko Ikeda, Takayuki Nojima, Hiroyuki Tsuchiya were incorrectly given as Y. Araki, N. Yamamoto, K. Hayashi, A. Takeuchi, S. Miwa, K. Igarashi, T. Higuchi, K. Abe, Y. Taniguchi, H. Yonezawa, S. Morinaga, Y. Asano, H. Ikeda, T. Nojima, H. Tsuchiya.

In addition, the Article contains a typographical error in the Results section, in the number of years in the ROC curve analyses for the optimal cut-off values.

“The optimal cut-off values were as follows: age, 47 years old (area under the curve [AUC], 0.59); size, 93 mm (AUC, 0.53); number of osteoclasts in the biopsy specimen, 5 (AUC, 0.75), number of courses of DOX as neoadjuvant chemotherapy, 3 (AUC, 0.63); number of courses of CDDP as neoadjuvant chemotherapy, 3 (AUC, 0.65); number of courses of IFO as neoadjuvant chemotherapy, 4 (AUC, 0.51), and number of courses of MTX as neoadjuvant chemotherapy, 1 (AUC, 0.48) (Table 1).”

now reads:

“The optimal cut-off values were as follows: age, 46 years old (area under the curve [AUC], 0.59); size, 93 mm (AUC, 0.53); number of osteoclasts in the biopsy specimen, 5 (AUC, 0.75), number of courses of DOX as neoadjuvant chemotherapy, 3 (AUC, 0.63); number of courses of CDDP as neoadjuvant chemotherapy, 3 (AUC, 0.65); number of courses of IFO as neoadjuvant chemotherapy, 4 (AUC, 0.51), and number of courses of MTX as neoadjuvant chemotherapy, 1 (AUC, 0.48) (Table 1).”

The number of years has been correctly shown in Table 1.

Furthermore, in Table 2, in the subcategory Stage,

“II/IV”

now reads:

“III/IV”

Published online: 19 April 2021

These errors have now been corrected in the PDF and HTML versions of the Article.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2021